Biotech IV Monitor

ERAS — Erasca Inc.

$6.5B market cap · 1 upcoming readout tracked

Clinical trial readout dates for Erasca Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is April 2028.

Next readoutApril 2028in ~17 months
Upcoming readouts11 Phase 3
Market cap$6.5B
Cash & investments$1.25B~24 quarters at last loss rate
Recent 8-K filings1latest 2026-11-12

Recently completed

The registry reports these trials have finished collecting primary data. Results often follow within months, and the company may already have reported.

Phase 1/2 ERAS-007
Advanced or Metastatic Solid Tumors · NCT04866134
July 2026
Primary data collected

Upcoming readouts

Phase 3 Naporafenib
Advanced or Metastatic NRAS-mutant Melanoma · NCT06346067
April 2028
Ongoing

Cash position

Erasca Inc. reported $1.25B in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-12). Its net loss for that quarter was $51M; at that rate the cash would last about 24 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.

Recent SEC filings

8-K Results of Operations — earnings, may carry pipeline updates2026-11-12

Companies working on similar indications

Discussion

No messages yet. If you follow ERAS, you can start the conversation.
Track ERAS in real time
See live implied volatility for ERAS and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on ERAS
Contact — questions or corrections about ERAS: dukeupt@gmail.com